Guideline for diagnosis and comprehensive treatment of colorectal liver metastases (version 2025)

The liver is the main target organ for hematogenous metastases from colorectal cancer, and colorectal liver metastasis is one of the most difficult and challenging situations in the treatment. In order to improve the diagnosis and comprehensive treatment in China, the Guidelines have been edited and revised for seven times since 2008, including the overall evaluation, personalized treatment goals and comprehensive treatments, to prevent the occurrence of liver metastases, increase the local damage rate of liver metastases, prolong long-term survival, and improve quality of life. The revised Guideline version 2025 includes the diagnosis and follow-up, prevention, multidisciplinary team (MDT), surgery and local ablative treatment, neoadjuvant and adjuvant therapy, comprehensive treatment. The revised Guideline emphasizes precision treatment based on genetic molecular typing, especially recommending immune checkpoint inhibitors for dMMR/MSI-H patients, and enriched local treatment methods, such as liver transplantation, yttrium-90 microsphere selective internal radiotherapy, etc. The revised Guideline includes state-of-the-art experience and findings, detailed content, and strong operability.

肝脏是结直肠癌血行转移最主要的靶器官，而且结直肠癌肝转移是结直肠癌治疗的重点和难点之一。为了提高我国结直肠癌肝转移的诊断和综合治疗水平，自2008年起联合编写《中国结直肠癌肝转移诊断和综合治疗指南》并后续进行了7次修订，以期指导对患者进行全面评估，精准地制定个体化的治疗目标，开展综合治疗，达到预防肝转移发生、提高肝转移灶局部毁损率、延长长期生存和改善生活质量的目的。本次修订后的2025版《指南》对以往结直肠癌肝转移的诊断和随访、预防、多学科团队（MDT）作用、手术等毁损治疗、新辅助和辅助治疗、综合治疗等六部分内容进行更新，强调基于基因分子分型的精准治疗，尤其推荐错配修复缺陷/高微卫星不稳定（dMMR/MSI-H）患者行免疫检查点抑制剂治疗，并丰富了局部治疗手段，如肝移植、钇-90微球选择性内放射治疗等。整体内容汇集总结国内外先进经验和最新成果，内容详尽，可操作性强。.